Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization
AuthorsAwan, Farrukh T.
Kochuparambil, S. Thomas
MetadataShow full item record
AbstractThe combination of filgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood progenitor cell collection. In this paper we describe our experience from two North American transplant centers in a series of patients who received salvage plerixafor while failing chemotherapy and G-CSF mobilization. Patients received a median of two doses of plerixafor salvage upon failure to mobilize adequate number of peripheral blood progenitor cells at neutrophil recovery. The use of plerixafor was associated with a 2.4-fold increase in peripheral blood CD34+ cell count and 3.9-fold increase in total CD34+ cell yield. All patients were able to collect â ¥2 Ã 106 CD34+â cells/kg with this approach. These results were more pronounced in patients with a higher CD34+ cell count at the time of the first plerixafor dose. Interestingly, peripheral blood white blood cell count was not shown to correlate with a response to plerixafor. Our results provide safety and efficacy data for the use of plerixafor in patients who are destined to fail chemomobilization.
CitationJ Oncol. 2012 Apr 10; 2012:931071
- New strategies for stem cell mobilization.
- Authors: Lemoli RM
- Issue date: 2012
- Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.
- Authors: Kouroukis CT, Varela NP, Bredeson C, Kuruvilla J, Xenocostas A
- Issue date: 2016 Aug
- The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
- Authors: Sivgin S, Karakus E, Kaynar L, Kurnaz F, Pala C, Keklik M, Zararsiz G, Solmaz M, Eser B, Cetin M, Unal A
- Issue date: 2013 Jun
- Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization.
- Authors: Bakeer M, Zubair AC, Roy V
- Issue date: 2020 Jan